P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial

P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial

Bibliographic Details
Main Authors:	Joseph F Merola, Subhashis Banerjee, Eric Morand, Piotr Leszczyński, Marilyn Pike, Ronald F van Vollenhoven, Coburn Hobar, Kathryn H Dao, Samantha Pomponi, Matthew J Colombo, Ravi Koti, Thomas Wegman
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-03-01
Series:	Lupus Science and Medicine

Similar Items

O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus
by: Laura Geraldino-Pardilla, et al.
Published: (2024-03-01)

P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study
by: Richard Furie, et al.
Published: (2024-03-01)

S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study
by: S Banerjee, et al.
Published: (2022-10-01)

LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study
by: Chun Wu, et al.
Published: (2023-07-01)

Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib
by: Arianna Zhang, BS, et al.
Published: (2024-03-01)

PaisleyTrees: A Size-Invariant Tree Visualization
by: Katayoon Etemad, et al.
Published: (2014-10-01)

Paisleys and other textile designs from India /
by: Prakash, K
Published: (1994)

Deucravacitinib in the treatment of psoriasis
by: Tomás Estevinho, et al.
Published: (2023-12-01)

The Language of Conflict in Northern Ireland: Gerry Adams vs. Ian Paisley
by: Kim Grego
Published: (2010-03-01)

LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus
by: Bindu Murthy, et al.
Published: (2023-07-01)

A Practical Study of Control in Objected-Oriented–Functional–Logic Programming with Paisley
by: Baltasar Trancón y Widemann, et al.
Published: (2017-01-01)

25 Disease modification in SLE: an introduction
by: Ronald van Vollenhoven
Published: (2023-09-01)

Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials
by: Joseph F. Merola, et al.
Published: (2025-02-01)

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
by: Neil J. Korman, et al.
Published: (2024-12-01)

22 New and approved therapies for SLE: Anifrolumab
by: Ronald van Vollenhoven
Published: (2022-04-01)

Treatment of hypertrophic lichen planus using deucravacitinib
by: Siddhartha Sood, HBSc, et al.
Published: (2024-09-01)

Discoid lupus erythematosus successfully treated with deucravacitinib
by: Nnenna Ezeh, MD, et al.
Published: (2024-07-01)

Treatment of oral lichen planus using deucravacitinib
by: Mindy Vu, BS, et al.
Published: (2024-02-01)

Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE
by: Jun Kang, et al.
Published: (2023-11-01)

Targeting DORIS Remission and LLDAS in SLE: A Review
by: Agner R. Parra Sánchez, et al.
Published: (2023-10-01)

Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis
by: David A. De Luca, et al.
Published: (2024-12-01)

Pityriasis rosea-like drug eruption secondary to deucravacitinib
by: Nisal Punchihewa, MD, et al.
Published: (2024-11-01)

Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
by: Ana Martins, et al.
Published: (2023-05-01)

String of successful trials in SLE: have we cracked the code?
by: Ronald van Vollenhoven
Published: (2020-10-01)

01 Understanding and treating SLE: a new era is dawning
by: Ronald van Vollenhoven
Published: (2020-09-01)

10 Novel concepts in SLE: Is it time for a new taxonomy?
by: Ronald van Vollenhoven
Published: (2022-04-01)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
by: Potestio L, et al.
Published: (2023-05-01)

Paisley-shaped antler onlays with fantastic beasts from Veliky Novgorod: issues of functional and stylistic attribution
by: Tochilova Nadezhda N., et al.
Published: (2024-12-01)

Correction: Targeting DORIS Remission and LLDAS in SLE: A Review
by: Agner R. Parra Sánchez, et al.
Published: (2024-06-01)

06 Interferon inhibition and the future management of SLE
by: Eric Morand
Published: (2021-04-01)

Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib
by: Nicole Bouché, BS, et al.
Published: (2023-09-01)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
by: Jin JQ, et al.
Published: (2023-05-01)

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial
by: Ian M. Catlett, et al.
Published: (2024-09-01)

Associations of metabolic syndrome in SLE
by: Eric Morand, et al.
Published: (2020-10-01)

05 Approved biologics for SLE: which to try first and in which patients? – The case for belimumab
by: Ronald van Vollenhoven
Published: (2023-09-01)

Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways
by: Brandon Johnson, et al.
Published: (2024-09-01)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
by: Kavanaugh, A, et al.
Published: (2024)

Treatment of discoid lupus erythematosus scarring alopecia with deucravacitinib: A case report
by: Katherine Aw, et al.
Published: (2025-01-01)

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
by: Shan Jing, et al.
Published: (2023-11-01)

Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
by: Sarah Oliel, et al.
Published: (2023-11-01)